O
1.24
-0.01 (-0.80%)
| 前收盘价格 | 1.25 |
| 收盘价格 | 1.26 |
| 成交量 | 1,745,740 |
| 平均成交量 (3个月) | 1,231,123 |
| 市值 | 297,231,744 |
| 价格/销量 (P/S) | 51.50 |
| 股市价格/股市净资产 (P/B) | 71.66 |
| 52周波幅 | |
| 利润日期 | 21 Feb 2025 - 25 Feb 2025 |
| 营业毛利率 | -135.10% |
| 营业利益率 (TTM) | -140.87% |
| 稀释每股收益 (EPS TTM) | -0.040 |
| 季度收入增长率 (YOY) | 15.10% |
| 总债务/股东权益 (D/E MRQ) | 15.22% |
| 流动比率 (MRQ) | 4.34 |
| 营业现金流 (OCF TTM) | -6.51 M |
| 杠杆自由现金流 (LFCF TTM) | -4.91 M |
| 资产报酬率 (ROA TTM) | -25.04% |
| 股东权益报酬率 (ROE TTM) | -134.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | ORTHOCELL FPO [OCC] | - | - |
AIStockmoo 评分
0.3
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.25 |
|
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 21.75% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合